Skip to main content
Equibles
PAVM logo

PAVM · PAVmed Inc. · Metrics

Track PAVM — free

Use PAVM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PAVM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.71 +0.14 (+8.86%) Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$12.56M
Shares
8.00M
Volume · Nov 9 1325 Avg daily vol (3M) 30.39K

PAVM metrics

70 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.57
Market cap
$12.56M

Price action

23 metrics
Price change (1W)
-19.5%
Price change (30D)
-43.7%
Price change (3M)
-66.9%
Price change (6M)
-78.1%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
138.3%
Annualized volatility (3M)
93.9%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.2
RSI (14D)
21.6
Price vs SMA 50
-51.3%
Price vs SMA 200
-75.4%
Avg volume (3M)
30,390
Relative volume
0.3
Average dollar volume
$121,377

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
8.00M

Valuation

12 metrics
P / E (TTM)
1.5
Trailing earnings · reciprocal yield 67.5%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
112.1×
reciprocal yield 0.9%
P / book
0.4
reciprocal yield 279.1%
FCF yield
-62.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-96.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
126.1×
reciprocal yield 0.8%
EV / revenue historical average (5Y)
127.3×
reciprocal yield 0.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-13
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
-221.4%
Operating margin
-23,841.1%
Trailing 12 months
Net margin
-10,794.6%
Gross profit (TTM)
−$248,000
Operating profit (TTM)
−$26.70M
Net income (TTM)
−$12.09M
Trailing 12 months
Diluted EPS (TTM)
$1.06
FCF margin
-6,948.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$36.60

Growth

11 metrics
Revenue growth YoY
+450.0%
Year over year
Net income growth YoY
-99.0%
Revenue (TTM)
$112,000
Trailing 12 months
EPS growth YoY
-137.8%
Shares change YoY
+940.0%
Year over year · more shares
Revenue CAGR (3Y)
-42.7%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-34.5%
Return on assets
-30.1%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
−$26.62M
Free cash flow (TTM)
−$7.78M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$3.78M
Latest balance sheet
Cash & equivalents
$3.78M
Total assets
$40.21M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.73M
Capital expenditures (TTM)
$52,000
R&D (TTM)
$6.37M
SG&A (TTM)
—
Stock compensation (TTM)
$1.71M
R&D / revenue
5,687.5%
Stock compensation / revenue
1,530.4%

Ownership (13F)

9 metrics
13F filers
20
13F filer change QoQ
0
Institutional ownership
11.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
6.3%
Private-fund adviser ownership
6.3%
Active holders' share change QoQ
+63.4%
Holder tenure
6.6
Price vs estimated holder cost
-34.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.0%

Short interest

3 metrics
Short interest
0.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1624326 CUSIP 70387R502 13F (30d) 17 filings 9 filers Visit website Investor relations